الفهرس 
HEPATITIS C VIRUSOnly 14 pages are availabe for public view
 |  | from | 181 |  |  |
| | | from | 181 | | |
Abstract
Background: Hepatitis C virus (HCV) infects 130 to 170 million people worldwide and up to 4 million individuals are newly infected with HCV annually Up to 64–82% of acutely infected individuals fail to clear the virus and thus develop chronic hepatitis C (CHC), with as many as 10–20% progressing to cirrhosis over 20–30 years. Aim of the Study: The aim of the study is to assess the validity of using a new rapid test (OraQuick) for screening of HCV infection in saliva in pregnant women. This cross sectional study was conducted in obstetrics & gynecology clinic in Ain Shams University hospital. It was included patients with known and unknown maternity anti-HCV antibody status, to define sensitivity and specificity of a new non-invasive test for HCV in saliva in diagnosis of HCV infection in pregnant women, from June 2014 to December 2015. Results: ORA test was +ve in 12 cases out of 15 cases +ve by PCR While Elisa test was +ve in 15 cases out of 15 cases +ve by PCR. highly statistically significant between ORA and Elisa, using Chi-square test, with p-value <0.001 HS. The study showed also highly statistically significant between Elisa and PCR, using Chi-square test, with p-value <0.001 HS. Conclusion: It is essential for policymakers and hospital administrators to know that the performances of point-of-care tests for detection of anti-HCV vary widely. Recommendations: The rapid HCV tests including Oraquick test will be widely used to various medical and non-medical environments in the future.